Statins as Targeted “Magical Pills” for the Conservative Treatment of Endometriosis: May Potential Adverse Effects on Female Fertility Represent the “Dark Side of the Same Coin”? A Systematic Review of Literature

The aim of the study was to analyze all the available evidence from both in vitro and in vivo studies regarding the efficacy of statin therapy in the treatment of endometriosis, evaluating the potential efficacy, side effects, and contraindications of their administration in humans. We focused on defining the potential benefits that the administration of statins may have on patients affected by endometriosis and the possible adverse effects of such a therapy on ovarian function and fertility profile. According to our article selection criteria, we included in the review in vitro and in vivo studies performed on human or animal models. The systematic review of literature identified 24 eligible articles, 12 of which reported evidence regarding the effects of statins on endometrial/endometriotic cells and 12 regarding their effects on ovarian function and fertility. All articles seem to emphasize the utility of statin administration in the treatment of endometriosis due to their anti-proliferative/proapoptotic effects, their ability to reduce cell viability and migration, and the inhibition of angiogenesis and anti-inflammatory activities. Regarding the potential adverse effects on gonadal activities, steroidogenesis and fertility function, no conclusive data were collected in human models (excluding women affected by polycystic ovary syndrome in which significant decline of androgen levels was reported after statin treatment), while contrasting results were reported by studies conducted in in vitro and in vivo in animal models. Despite evidence supporting statins as the potential therapeutic agent for a targeted conservative treatment of endometriosis, the uncertainties regarding their impact on gonadal function may not define them as an appropriate therapy for all young fertile women. Similar content being viewed by others

Giudice LC, Kao LC. Endometriosis. Lancet. 2004; 364(9447):1789–1799. Rogers PA, D’Hooghe TM, Fazleabas A, et al. Defining future directions for endometriosis research:workshop report from the 2011 World Congress of Endometriosis in Montpellier, France. Reprod Sci. 2013; 20(5):483–499. Patrelli TS, Berretta R, Gizzo S, et al. CA 125 serum values in surgically treated endometriosis patients and its relationships with anatomic sites of endometriosis and pregnancy rate. Fertil Steril. 2011; 95(1):393–396. Luisi S, Lazzeri L, Ciani V, Petraglia F. Endometriosis in Italy:from cost estimates to new medical treatment. Gynecol Endocrinol. 2009; 25(11):734–740. Minici F, Tiberi F, Tropea A, et al. Endometriosis and human infertility:a new investigation into the role of eutopic endome-trium. Hum Reprod. 2008; 23(3):530–537. Nnoaham KE, Hummelshoj L, Webster P, et al. Impact of endo-metriosis on quality of life and work productivity:a multicenter study across ten countries. Fertil Steril. 2011; 96(2):366–373.e8. Aznaurova YB, Zhumataev MB, Roberts TK, Aliper AM, Zha-voronkov AA. Molecular aspects of development and regulation of endometriosis. Reprod Biol Endocrinol. 2014; 12:50. Jiang QY, Wu RJ. Growth mechanisms of endometriotic cells in implanted places:a review. Gynecol Endocrinol. 2012; 28(7):562–567. Hey-Cunningham AJ, Markham R, Fraser IS, Berbic M. Dysregu-lation of vascular endothelial growth factors and their neuropilin receptors in the eutopic endometrium of women with endometrio-sis. Reprod Sci. 2013; 20(11):1382–1389. Poncelet C, Cornelis F, Tepper M, et al. Expression of E- and N-cadherin and CD44 in endometrium and hydrosalpinges from infertile women. Fertil Steril. 2010; 94(7):2909–2912. Béliard A, Donnez J, Nisolle M, Foidart JM. Localization of lami-nin, fibronectin, E-cadherin, and integrins in endometrium and endometriosis. Fertil Steril. 1997; 67(2):266–272. Sokalska A, Cress A, Bruner-Tran KL, et al. Simvastatin decreases invasiveness of human endometrial stromal cells. Biol Reprod 2012;87(1):21–6. Lee DH, Kim SC, Joo JK, et al. Effects of 17β-estradiol on the release of monocyte chemotactic protein-1 and MAPK activity in monocytes stimulated with peritoneal fluid from endometriosis patients. J Obstet Gynaecol Res. 2012; 38(3):516–525. Cakmak H, Basar M, Seval-Celik Y, et al. Statins inhibit mono-cyte chemotactic protein I expression in endometriosis. Reprod Sci. 2012; 19(6):572–579. Iba Y, Harada T, Horie S, Deura I, Iwabe T, Terakawa N. Lipopolysaccharide-promoted proliferation of endometriotic stro-mal cells via induction of tumor necrosis factor alpha and interleukin-8 expression. Fertil Steril. 2004; 82(suppl 3):1036–1042. Almassinokiani F, Mehdizadeh A, Sariri E, et al. Effects of sim-vastatin in prevention of pain recurrences after surgery for endo-metriosis. Med Sci Monit. 2013; 19:534–539. American College of Obstetricians and Gynecologists:Practice bulletin no. 114: management of endometriosis. Obstet Gynecol. 2010; 116(1):223–236. Brown J, Farquhar C. Endometriosis:an overview of Cochrane reviews. Cochrane Database Syst Rev. 2014; (3):CD009590. Bruner-Tran KL, Osteen KG, Duleba AJ. Simvastatin protects against the development of endometriosis in a nude mouse model. J Clin Endocrinol Metab. 2009; 94(7):2489–2494. Taylor HS, Osteen KG, Bruner-Tran KL, et al. Novel therapies targeting endometriosis. Reprod Sci. 2011; 18(9):814–823. Panay N. Advances in the medical management of endometriosis. BJOG. 2008; 115(7):814–817. Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013; (1):CD004816. McFarlane SI, Muniyappa R, Francisco R, Sowers JR. Clinical review 145:pleiotropic effects of statins:lipid reduction and beyond. J Clin Endocrinol Metab. 2002; 87(4):1451–1458. Gizzo S, Ancona E, Noventa M, D’Antona D, Nardelli GB. Long-term statin use and risk of breast cancer—letter. Cancer Epidemiol Biomarkers Prev. 2014; 23(1):218. Gizzo S, Noventa M, Saccardi C, Litta P, D’Antona D, Nardelli GB. Proposal on raloxifene use after prophylactic salpingo-oophorectomy in BRCA1–2:hypothesis and rationale. Eur J Cancer Prev 2014;23(6):514–515. Gizzo S, Saccardi C, Patrelli TS, et al. Update on raloxifene:mechanism of action, clinical efficacy, adverse effects, and contraindications. Obstet Gynecol Surv. 2013; 68(6):467–481. Gizzo S, Noventa M, Di Gangi S, et al. Could in-vitro studies on Ishikawa cell lines explain the endometrial safety of raloxifene? Systematic literature review and starting points for future oncological research [published online December 22, 2014]. Eur J Cancer Prev. 2014. Sokalska A, Wong DH, Cress A, et al. Simvastatin induces apop-tosis and alters cytoskeleton in endometrial stromal cells. J Clin Endocrinol Metab. 2010; 95(7):3453–3459. Piotrowski PC, Kwintkiewicz J, Rzepczynska IJ, et al. Statins inhibit growth of human endometrial stromal cells independently of cholesterol availability. Biol Reprod. 2006; 75(1):107–111. Sokalska A, Anderson M, Villanueva J, et al. Effects of simvasta-tin on retinoic acid system in primary human endometrial stromal cells and in a chimeric model of human endometriosis. J Clin Endocrinol Metab. 2013; 98(3):E463–E471. Izquierdo D, Foyouzi N, Kwintkiewicz J, Duleba AJ. Mevastatin inhibits ovarian theca-interstitial cell proliferation and steroido-genesis. Fertil Steril. 2004; 82(suppl 3):1193–1197. Sokalska A, Piotrowski PC, Rzepczynska IJ, Cress A, Duleba AJ. Statins inhibit growth of human theca-interstitial cells in PCOS and non-PCOS tissues independently of cholesterol availability. J Clin Endocrinol Metab. 2010; 95(12):5390–5394. Kwintkiewicz J, Foyouzi N, Piotrowski P, Rzepczynska I, Duleba AJ. Mevastatin inhibits proliferation of rat ovarian theca-interstitial cells by blocking the mitogen-activated protein kinase pathway. Fertil Steril. 2006; 86(4 suppl):1053–1058. Rzepczynska IJ, Piotrowski PC, Wong DH, Cress AB, Villanueva J, Duleba AJ. Role of isoprenylation in simvastatin-induced inhibition of ovarian theca-interstitial growth in the rat. Biol Reprod. 2009; 81(5):850–855. Sokalska A, Stanley SD, Villanueva JA, Ortega I, Duleba AJ. Comparison of effects of different statins on growth and steroido-genesis of rat ovarian theca-interstitial cells. Biol Reprod. 2014; 90(2):44. Nasu K, Yuge A, Tsuno A, Narahara H. Simvastatin inhibits the proliferation and the contractility of human endometriotic stromal cells:a promising agent for the treatment of endometriosis. Fertil Steril. 2009; 92(6):2097–2099. Sharma I, Dhawan V, Mahajan N, Saha SC, Dhaliwal LK. In vitro effects of atorvastatin on lipopolysaccharide-induced gene expression in endometriotic stromal cells. Fertil Steril. 2010; 94(5):1639–1646.e1. Esfandiari N, Khazaei M, Ai J, et al. Effect of a statin on an in vitro model of endometriosis. Fertil Steril. 2007; 87(2):257–262. Rung E, Friberg PA, Shao R, et al. Progesterone-receptor antagonists and statins decrease de novo cholesterol synthesis and increase apoptosis in rat and human periovulatory granulosa cells in vitro. Biol Reprod. 2005; 72(3):538–545. Rung E, Friberg PA, Bergh C, Billig H. Depletion of substrates for protein prenylation increases apoptosis in human periovulatory granulosa cells. Mol Reprod Dev. 2006; 73(10):1277–1283. Ortega I, Cress AB, Wong DH, et al. Simvastatin reduces steroi-dogenesis by inhibiting Cyp17a1 gene expression in rat ovarian theca-interstitial cells. Biol Reprod. 2012; 86(1):1–9. Oktem M, Esinler I, Eroglu D, Haberal N, Bayraktar N, Zeyneloglu HB. High-dose atorvastatin causes regression of endometrio-tic implants:a rat model. Hum Reprod. 2007; 22(5):1474–1480. Yilmaz B, Ozat M, Kilic S, et al. Atorvastatin causes regression of endometriotic implants in a rat model. Reprod Biomed Online. 2010; 20(2):291–299. Engelhardt H, Gore-Langton RE, Armstrong DT. Mevinolin (lovastatin) inhibits androstenedione production by porcine ovarian theca cells at the level of the 17 alpha-hydroxylase:C-17, 20-lyase complex. Endocrinology. 1989; 124(5):2297–2304. Plotkin D, Miller S, Nakajima S, et al. Lowering low density lipo-protein cholesterol with simvastatin, a hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, does not affect luteal function in premenopausal women. J Clin Endocrinol Metab. 2002; 87(7):3155–3161. Elkin RG, Yan Z. Relationship between inhibition of mevalonate biosynthesis and reduced fertility in laying hens. J Reprod Fertil. 1999; 116(2):269–275. Zapata R, Piulachs MD, Bellés X. Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase lower fecundity in the German cockroach:correlation between the effects on fecundity in vivo with the inhibition of enzymatic activity in embryo cells. Pest Manag Sci. 2003; 59(10):1111–1117. Gibran L, Maranha~o RC, Abra~o MS, Baracat EC, Podgaec S. Could statins constitute a novel treatment for endometriosis? Systematic review of the literature. Eur J Obstet Gynecol Reprod Biol. 2014; 179:153–158. Godfrey LM, Erramouspe J, Cleveland KW. Teratogenic risk of statins in pregnancy. Ann Pharmacother. 2012; 46(10):1419–1424. doi:10.1345/aph.1R202. Taguchi N, Rubin ET, Hosokawa A, et al. Prenatal exposure to HMG-CoA reductase inhibitors:effects on fetal and neonatal outcomes. Reprod Toxicol. 2008; 26(2):175–177. Gizzo S, Andrisani A, Esposito F, et al. Which luteal phase support is better for each IVF stimulation protocol to achieve the highest pregnancy rate? A superiority randomized clinical trial [published online September 30, 2014]. Gynecol Endocrinol. 2014:1–7. Gizzo S, Andrisani A, Esposito F, et al. Ovarian reserve test:an impartial means to resolve the mismatch between chronological and biological age in the assessment of female reproductive chances. Reprod Sci. 2014; 21(5):632–639. Gizzo S, Capuzzo D, Zicchina C, et al. Could empirical low-dose-aspirin administration during IVF cycle affect both the oocytes and embryos quality via COX 1–2 activity inhibition? J Assist Reprod Genet. 2014; 31(3):261–268. Author information Authors and Affiliations Corresponding author Rights and permissions About this article Cite this article Vitagliano, A., Noventa, M., Quaranta, M. et al. Statins as Targeted “Magical Pills” for the Conservative Treatment of Endometriosis: May Potential Adverse Effects on Female Fertility Represent the “Dark Side of the Same Coin”? A Systematic Review of Literature. Reprod. Sci. 23, 415–428 (2016). https://doi.org/10.1177/1933719115584446 Published: Issue date: DOI: https://doi.org/10.1177/1933719115584446